Quantitative analysis of the erythrocyte membrane proteins in polycythemia vera patients treated with hydroxycarbamide  by Kottahachchi, Darshana et al.
Q
p
h
D
D
A
a
U
b
F
c
d
e
f
g
N
a
A
R
R
2
A
A
K
E
p
P
J
Q
M
P
N
h
2
Ce u  p a o p e n p r o t e o m i c s 7 ( 2 0 1 5 ) 43–53
Available  online  at  www.sciencedirect.com
ScienceDirect
journa l h om epa ge: ht tp : / /www.e lsev ier .com/ locate /euprot
uantitative  analysis  of  the erythrocyte  membrane
roteins in polycythemia  vera  patients  treated with
ydroxycarbamide
arshana Kottahachchia, Lallindra Gooneratned, Anil Jayasekerae,
orota Muth-Pawlakb, Robert Moulderb, Susumu Y. Imanishib,f,
ri  Ariyaratnec, Anne Rokkab, Garry L. Corthalsb,g,∗
Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, General Sir John Kotelawala Defence
niversity, Sri Lanka
Turku Centre for Biotechnology, University of Turku and Åbo Academy University, Tykistokatu 6, FI-20520 Turku,
inland
Department of Physics, Faculty of Science, University of Colombo, Colombo 00300, Sri Lanka
Department of Pathology, Faculty of Medicine, University of Colombo, Colombo 00800, Sri Lanka
Department of Plant Sciences, Faculty of Science, University of Colombo, Colombo 00300, Sri Lanka
Faculty of Pharmacy, Meijo University, Nagoya 468-8503, Japan
Van ‘t Hoff Institute for Molecular Sciences (HIMS), University of Amsterdam, 1098 XH Amsterdam, The
etherlands
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 23 September 2014
eceived in revised form
4 April 2015
ccepted 24 April 2015
vailable online 5 May 2015
eywords:
rythrocyte membrane associated
roteins
a  b  s  t  r  a  c  t
More than 90% of polycythemia vera (PV) patients have a mutation in the protein JAK2,
which is closely associated with the erythrocyte membrane. With the comparison of 1-D gels
of  erythrocyte membranes obtained from PV patients treated with hydroxycarbamide and
those of untreated controls we observed signiﬁcant differences in the region of 40–55 kDa.
On  the basis of the LC–MS/MS analysis of this region we report up-regulation of four protein
disulﬁde isomerases, which was subsequently conﬁrmed by targeted mass spectrometric
analysis. In further studies it will be prudent to compare this in patients both treated and
not treated with hydroxycarbamide.
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1.  Introduction
Polycythemia vera (PV) is a myeloproliferative neoplasm
originating from the clonal proliferation of a pluripo-
tent hemopoietic progenitor characterized by erythrocytosis,
which is an increase in the red blood cell mass. Erythrocytosis,
which is the hallmark of PV, can result in life threatening clin-
ical effects such as venous or arterial thrombosis [1]. In 2005,
a unique acquired mutation was identiﬁed in the cytoplasmic
tyrosine kinase JAK2 (Janus kinase 2) in myeloid cells of over
90% of PV patients. It has since been demonstrated that the
JAK2 V617F mutation plays a central role in the diagnosis of PV
and can be used as a way of differentiating neoplastic myeloid
proliferations from reactive ones [1,2]. The V617F mutation is
known to result in the production of a constitutively activated
JAK2 protein, which autophosphorylates JAK2 itself [3]. This in
turn leads to cytokine independent erythrocytosis [4]. EpoR is a
transmembrane receptor, which, in a healthy person, requires
binding of its ligand, Epo, to its extracellular domain. The bind-
ing initiates the process of phosphorylation by JAK2, which
is associated with the cytoplasmic domain of EpoR in close
proximity to the erythrocyte membrane [5,6].
Mass spectrometry based proteomics technologies have
successfully been used to establish protein proﬁles of the
mature erythrocyte, including post-translational modiﬁca-
tions [7–11]. In contrast to proteomics, the absence of a nucleus
in the mature erythrocyte has made mRNA  based micro array
approaches inapplicable. As no convenient biomarker exists
today for PV, screening the erythrocyte content by differential
proteomics could help in ﬁnding more  efﬁcient diagnosis tests
[12]. Alterations of erythrocyte membrane associated pro-
teins (ERMBPs) have caused erythrocyte membrane disorders
such as hereditary spherocytosis and hereditary elliptocyto-
sis. Therefore ERMBPs have been the focus of investigation
for several hematological disorders in humans [13–15]. As ery-
throcytosis is a characteristic feature of PV disease and JAK2
protein is closely associated with the erythrocyte membrane,
protein abundance changes in the erythrocyte membrane
is an ideal target to study mechanisms of this disorder.
Although the defect arises from bone marrow stem cells of
PV, pathological changes may occur in the mature erythro-
cyte. For instance, in chronic myeloid leukemia which is one
of the myeloproliferative disorders like PV, patients suffer
from anemia, and neutrophilic cathepsin G from serum medi-
ates cleavage of erythrocyte membrane protein band 3, which
enhances phagocytosis of erythrocytes [16]. In previous stud-
ies of PV surface-enhanced laser desorption/ionization mass
spectrometry has been used for the analysis of serum pro-
teins, differentiating two PV sub groups and also PV from
essential thrombocythemia [17,18]. As a target for erythro-
cyte proteomics, analysis of erythrocyte membrane fractions
would also be interesting as it sets the stage for protein expres-
sion and function-based activity proﬁling [7,8,10].
In this paper, we  will focus on the quantitative pro-
teomics analysis of erythrocyte membranes in PV patients
with the JAK2 V617F mutation and healthy controls. At
the time of investigation all patients were treated with
hydroxycarbamide, which is a metabolic inhibitor of ribonu-
cleoside reductase and a non-alkylating myelosuppressive s 7 ( 2 0 1 5 ) 43–53
agent used to control the erythrocytosis [19]. Using 1-D gel
separation and a liquid chromatography–tandem mass spec-
trometry (LC–MS/MS) based label-free quantitative proteomics
approach, we found four potential differentially regulated
ERMBPs. The observed increased abundance of these candi-
dates was validated by selected reaction monitoring (SRM)
[20–22]. The four proteins belong to the protein disulﬁde
isomerase family (PDI), which is involved in oxidative stress
response [23]. In keeping with this, increased oxidative stress
has been previously reported in the serum of PV patients,
even though treatment alleviates the stress in part [24]. In
future studies, further validation of these candidate mark-
ers are planned to evaluate their diagnostic potential for the
detection of PV.
2.  Materials  and  methods
2.1.  Patients  and  controls
Blood samples were obtained from ﬁve PV patients with
the JAK2 V617F mutation (P1–P5) and ﬁve healthy volunteers
(N1–N5). All 5 patients were treated with hydroxycarbamide
and a low aspirin dose for over 6 months, displayed stable
blood counts (Table 1) and had also been subjected to multiple
therapeutic venesections. The patients (4 males and 1 female)
were between 40 and 60 years of age, while the healthy con-
trols (2 males and 3 females) were between 40 and 50 years of
age. A full blood count (FBC) was performed in all patients with
a Beckman Coulter hematology analyzer. Ethical clearance
was obtained from the Ethical Review Committee of Faculty
of Medicine, University of Colombo (Reference No: EC-11-007).
2.2.  Puriﬁcation  of  erythrocyte  membrane  proteins
Each of the 10 blood samples was mixed with 4%, w/v,  EDTA,
pH 7.4 as an anticoagulant at a ratio of 1:20. All the blood
samples were kept 4 days at +4 ◦C before analysis in order
to mature reticulocytes to erythrocytes. Erythrocytes were
obtained from the whole blood by washing it four times
with phosphate buffered saline, pH 8.0 employing low speed
centrifugation, 1500 × g for 10 min. A pellet of the washed
erythrocytes was kept at −80 ◦C for further analysis. Erythro-
cyte membrane fractions were isolated by osmotic lysis of
the washed erythrocytes using lysis solution (5 mM phosphate
buffer, pH 8.0, 1 mM EDTA) followed by high speed centrifuga-
tion, 24,000 x g for 10 min  [7]. This was repeated for 3 more
times and hemoglobin was removed with the supernatant
in each time. Protease inhibitors (Complete mini EDTA-free,
Roche Diagnostics GmBH, Mannheim, Germany) were added
to the lysing solution as well as to the washing solutions.
Finally, the isolated membranes were solubilized by 4% Tri-
ton X-100 in 10 mM Tris–HCl, pH 8.8. Total protein amounts
were estimated by the Lowry method (DC Protein assay, Bio-
Rad laboratories, Richmond, USA) using BSA for the standard
protein and also by measuring absorbance at A280 nm with a
NanoDrop 1000 spectrophotometer (Thermo Fisher Scientiﬁc,
Waltham, USA).
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Table 1 – Full blood count parameters and Jak2 status of PV patients (P1–P5) and controls (N1–N5).
PV patients Healthy controls Ref. value
P1 P2 P3 P4 P5 N1 N2 N3 N4 N5
JAK2 (V617F) (+) (+) (+) (+) (+) (−) (−) (−) (−) (−) (+) or (−)
WBC (×109/l) 14.2 10.9 10.8 14.7 16.7 5.4 4.8 6.7 6.3 5.8 4.0–11.0
Hb (g/dl) 12.4 15.9 13.8 14.8 10.4 13.3 14.5 13.7 13.6 12.7 12–17
RBC Count (×1012/l) 6.2 5.8 5.4 6.0 5.0 4.5 5.0 4.9 4.8 4.5 4.0–6.0
HCT (%) 39.7 49.4 43.2 47.3 34.7 39.7 43.2 41.4 40.7 37.8 35–50
Platelet count (×109/l) 388 140 345 332 155 280 272 297 257 307 150–450
MCV (ﬂ) 64.1 85.0 79.6 78.7 68.4 87.8 85.8 85.2 85.1 84.9 78–95
MCH (pg) 20.0 27.4 25.4 24.6 20.5 29.4 28.8 28.2 28.4 28.5 27–32
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MCHC, mean cell hemoglobin concentration.
.3.  1-D  SDS-PAGE  and  in-gel  trypsin  digestion  of
roteins
wenty micrograms  of the erythrocyte membrane proteins
f PV patients and healthy controls were separated on pre-
ast Tris-acetate gels (Criterion XT, 3–8% acrylamide, Bio-Rad)
sing Tricine running buffer. Proteins were silver stained as
escribed previously [25]. Gel bands of interest were cut, dehy-
rated with 100% acetonitrile and stored as dried ones at
20 ◦C. The proteins were digested in-gel with trypsin accord-
ng to the original protocol of Shevchenko et al. [26] with
inor modiﬁcations. Proteins were reduced with 20 mM DTT
nd alkylated with 55 mM iodoacetamide, prepared in 50 mM
H4HCO3. The gel pieces were swollen in a digestion buffer
ontaining 50 mM NH4HCO3 and 12.5 ng/l trypsin (Promega,
adison, USA) on ice. After 10 min, more  50 mM NH4HCO3
as added to the gel pieces to cover them, and digestion
as allowed to proceed overnight at 37 ◦C. The peptides were
xtracted by 50% acetonitrile, 5% formic acid. The supernatant
ontaining tryptic peptides was dried by vacuum centrifu-
ation. Prior to MS  analysis, the peptides were dissolved in
% formic acid. Total peptide amounts were estimated by
easuring absorbance at A280 nm with the NanoDrop 1000
pectrophotometer.
.4.  In-solution  trypsin  digestion  of  proteins  for  SRM
nalysis
he isolated membrane proteins from PV patients and healthy
ontrols were subjected to in-solution digestion. The proteins
ere reconstituted with 6 M urea, reduced with 10 mM DTT
nd alkylated with 40 mM iodoacetamide prepared in 25 mM
H4HCO3. Before adding trypsin the solution was diluted 10
imes with 25 mM NH4HCO3. The digestion was allowed to
roceed overnight at 37 ◦C with the additon of typsin at ratio of
–30 by weight. The Triton X-100, which was used for the mem-
rane protein isolation, was removed with Pierce detergent
emoval spin columns (Thermo Fisher Scientiﬁc). Following
cidiﬁcation of the solution containing tryptic peptides with
% formic acid, the peptides were desalted using Empore C18
olumns (3M, St. Paul, USA), then dried by vacuum centrifu-
ation. Prior to MS  analysis, the peptides were dissolved in 1%
ormic acid. Total protein amounts were estimated with the
anoDrop 1000 spectrophotometer. 33.5 33.5 33.1 33.4 33.6 30–35
2.5.  LC–MS/MS  for  identiﬁcation  and  non-targeted
quantiﬁcation  of  proteins
The in-gel digests were analyzed using a nanoﬂow liquid chro-
matography system (Ultimate 3000, Dionex, Sunnyvale, USA)
coupled to a QSTAR Elite ESI-hybrid Q-TOF tandem mass spec-
trometer (Applied Biosystems/MDS Sciex, Toronto, Canada).
Five microliters of peptide solutions (200 ng) were ﬁrst loaded
on a pre-column (0.3 mm × 5 mm,  PepMap C18, 5 m,  100 A˚, LC
Packings, Sunnyvale, USA) at a ﬂow rate of 18 l/min and sub-
sequently separated on an in-house packed analytical column
(75 m × 15 cm,  Magic C18AQ, 5 m,  200 A˚, Michrom BioRe-
sources, Sacramento, USA) at a ﬂow rate of 200 nl/min. The
mobile phase consisted of water/acetonitrile (98:2 (v/v)) with
0.2% formic acid (solvent A) or acetonitrile/water (95:5 (v/v))
with 0.2% formic acid (solvent B). LC gradient elution con-
dition was 2–35% B (0–20 min), 35–95% B (20–25 min), 95% B
(25–40 min), and then 2% B (40–45 min) with a ﬂow rate of
200 nl/min. MS data was acquired automatically using Analyst
QS 2.0 software (Applied Biosystems/MDS Sciex). An informa-
tion dependent acquisition method consisted of a one second
TOF MS  survey scan with a mass range 350–1500 m/z  and
maximum two seconds product ion scans with a mass range
50–2000 m/z. Two most intensive precursor ion peaks, with ion
counts over 20 and charge states 2+ or 3+, were selected for
fragmentation. Dynamic exclusion duration was 60 s.
2.6.  LC–MS/MS  for  creating  a  spectral  library
For designing a targeted quantitative method for the vali-
dation of the nine ERMBPs targets, ﬁrst the in-solution
digests from one healthy control (N4) and one PV patient
(P2) were analyzed using an Easy-nLC 1000 nanoﬂow liquid
chromatography system coupled to a Q Exactive ESI-hybrid
quadrupole-orbitrap mass spectrometer (Thermo Fisher Sci-
entiﬁc). Five microliters of the peptides (500 ng) were ﬁrst
loaded on an in-house packed pre-column (100 m × 2 cm,
Magic C18AQ), and subsequently separated on an in-house
packed analytical column at a ﬂow rate of 300 nl/min. The ana-
lytical column and the mobile phases were the same as those
used for the QSTAR Elite system. LC gradient elution condition
was 2–35% B (0–40 min), 35–100% B (40–42 min), and then 100%
B (42–50 min), with a ﬂow rate of 300 nl/min. Data dependent
acquisition was performed in positive ion mode. MS spectra
were acquired from m/z 300 to m/z 2000 at a resolution of 70,000
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at m/z 200 with a target value of 1,000,000 and maximum injec-
tion time of 120 ms.  The 10 most abundant precursor ions of
which charge states were 2+ or higher were selected for higher
energy collisional dissociation with an isolation window of 2
and normalized collision energy of 27. MS/MS spectra were
acquired at a resolution of 17,500 at m/z 200 with a target value
of 20,000, maximum injection time of 250 ms,  and the lowest
mass ﬁxed at m/z 100. Dynamic exclusion duration was 10 s.
2.7.  LC–MS/MS  for  SRM
A TSQ Vantage ESI-triple quadrupole mass spectrometer
(Thermo Fisher Scientiﬁc) was used for SRM analysis of the
in-solution digests. The LC system and conditions of chro-
matographic separation were same as described for the Q
Exactive system. Five hundred nanograms of the in-solution
digests were injected on the pre-column coupled to the ana-
lytical column for separation. The mass spectrometer was
controlled by Xcalibur software (version 2.2, Thermo Fisher
Scientiﬁc) and operated in the positive ion mode. A spray volt-
age of 2.3 kV, an ion source temperature of 275 ◦C, and Q1 and
Q3 set to unit/unit resolution (0.7 Da), 0.002 m/z scan width,
and a dwell time of at least 50 ms  was used. Using the opti-
mized method (described below), the in-solution digests of PV
patients and healthy controls were analyzed in duplicate. All
the Raw ﬁles were imported to Pinpoint 1.2 software (Thermo
Fisher Scientiﬁc) and data analysis was performed.
2.8.  Database  searches  and  gene  ontology  annotations
Database searches of the QSTAR Elite data were performed
by Mascot (version 2.2) (Matrix Science, London, UK) search
engine against Swiss-Prot database (2011 08) using a Homo
sapiens taxonomy ﬁlter (20,245 sequences). Carbamidomethy-
lation of cysteines was set as a ﬁxed modiﬁcation and
oxidation of methionines was set as a variable modiﬁcation.
One missed trypsin cleavage site was allowed. Mass tolerance
for MS  and MS/MS  was set to 0.3 Da, and only proteins identi-
ﬁed with minimum two unique peptides were selected. In case
of the Q Exactive data, Mascot search was preformed via Pro-
teome Discoverer (version 1.3, Thermo Fisher Scientiﬁc) with
the same parameters but mass tolerances for MS and MS/MS
were set to 10 ppm and 0.02 Da, respectively. Scaffold software
(version 3.3.2, Proteome software) and Uniprot database were
used to provide Gene Ontology (GO) annotations to proteins.
2.9.  Non-targeted  label-free  protein  quantiﬁcation
Relative quantiﬁcation of the in-gel digested proteins was car-
ried out by both spectral counting and by measuring precursor
ion intensity. Peptide-spectrum matches obtained from Mas-
cot results were counted manually for the identiﬁed proteins,
using unique peptides (required bold) with an expectation
value <0.05. The spectral counts were normalized to house-
keeping proteins, actin or basigin. For the proteins elected
for further quantiﬁcation, the associated unique peptides
were monitored with the extracted ion chromatograms (XICs,
±0.5 m/z), and the intensities of all the peptide ions were
summed to assess the protein abundances [12]. Relative abun-
dance of the protein was obtained after normalizing to basigin. s 7 ( 2 0 1 5 ) 43–53
2.10.  SRM  method  development
The preliminary analysis of in-solution digests on the Q Exac-
tive resulted in the identiﬁcation of 193 proteins (Scaffold,
99% protein conﬁdence, 95% peptide conﬁdence, minimum 2
peptides per protein), of which 135 were annotated as mem-
brane proteins. This data covered all the proteins targeted in
SRM (see the list of proteins below). Based on the Q Exac-
tive data and the QSTAR Elite data (in-gel digests), proteotypic
peptides were chosen as surrogates of the measured proteins
according to the following rules: zero missed cleavages, car-
bamidomethylation as a ﬁxed modiﬁcation, no methionine
residues present, excluded ragged ends and known post-
translational modiﬁcations. Up to six transitions per peptide
precursor ion were chosen, and up to six peptides (minimum
3) per protein were included in the list. Transitions for pro-
teotypic peptides were selected based on spectral libraries
created from the former data dependent experiments with
the Q Exactive and QSTAR Elite, when no match was found
the PeptideAtlas was addressed.
To optimize the method, one of the PV patient samples
(P1 in-solution digest) was used. Retention times were pre-
dicted based on the spectral library built from the Q Exactive
data to create a preliminary scheduled SRM method for opti-
mization. The iSRM technique (Thermo Fisher Scientiﬁc) was
applied in order to conﬁrm the identity of each peptide
and to choose the most intense transitions for quantitative
analysis. The peptides were targeted in a 3-min scheduled
acquisition window, monitoring for 2 primary and 4 secondary
transitions for each peptide. Once the intensity of the two tran-
sitions overcame the threshold of 300, instrument triggered
the intensity of six additional transitions for the same pep-
tide. The acquired MS/MS spectra were then compared with
the library spectra to conﬁrm that the major MS/MS  peaks
matched. For quantitative runs the four most intense transi-
tions per peptide were monitored within a 3 min  time window.
The ﬁnal list of targets included; 10 proteins, 36 peptides,
113 transitions (Supplementary Table 1). The collision energy
(CE) predicted by Pinpoint software (according to the equa-
tion: CE = 0.04 m/z − 3.88, for doubly; and CE = 0.04 m/z − 0.89,
for triply charged ions), was optimized for each transition in 5
steps of 3 eV. The best CE value for each transition was chosen
automatically in Pinpoint software.
For each of four transitions the area under the curve was
calculated by Pinpoint program separately, and these values
were then summed up to give the ﬁnal peptide abundance
in the sample. These values were used to calculate protein
abundance, which was then normalized by total area of the
reference protein basigin. Results were shown as relative
abundance ratios of proteins, patients to controls.
2.11.  Statistical  analysis  of  differentially  regulated
proteins
XIC and SRM data were normalized to the house-keeping
protein basigin before statistical data analysis. The normal-
ized data obtained from PV patients and healthy controls
were subjected to nonparametric Wilcoxon rank sum test
(Mann–Whitney test) using SPSS (Statistical Product and
Service Solutions) software (version 20).
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Fig. 1 – ERMBPs of PV patients (P1–P5) and healthy controls
(N1–N5) separated by SDS-PAGE. A representative gel is
shown (silver staining). An asterisk indicates a gel area of
interest (40–55 kDa).e u  p a o p e n p r o t e o 
.  Results  and  discussion
.1.  Hematological  parameters
he FBC results of patients and controls are summarized in
able 1. The white blood cell count (WBC) of the patients
P1–P5) ranged from 10.8 to 16.7 × 109/l with a mean value
f 13.5 × 109/l. This was considerably higher than the WBC  of
he control group (N1–N5) which ranged from 4.8 to 6.7 × 109/l
ith a mean value of 5.8 × 109/l. This is in accordance with
 characteristic feature of PV as it results in a panmyelosis
ith patients frequently having a leucocytosis. The red blood
ell count (RBC) of the patients ranged from 5.0 to 6.2 × 1012/l
ith a mean value of 5.7 × 1012/l and was higher than the con-
rol group, which had a RBC ranging from 4.5 to 5.0 × 1012/l
ith a mean value of 4.7 × 1012/l. The hemoglobin level in four
atients and all ﬁve controls were within the normal range.
ne patient (P5) was anemic (hemoglobin (Hb) = 10.4 g/dl) with
 low mean cell volume (MCV) and mean cell hemoglobin
MCH) which was likely to be due to iron deﬁciency follow-
ng repeated venesections. The hematocrit (HCT) of all ﬁve
atients and controls was within the normal range. Although
he HCT of patients was well controlled by venesections in
ombination with hydroxycarbamide, these treatments were
ot aiming at altering the underlying pathogenesis of the
isease. The platelet count of all but one patient (P2) was
Table 2 – ERMBPs identiﬁed by LC–MS/MS from a gel area of 40–
patient samples.
Protein and entry namea Accession
number
Mol. weig
(kDa)
Actin, cytoplasmic 1, ACTB P60709 41.7 
Basigin, BASI P35613 42.2 
cAMP-dependent protein kinase
type I-alpha regulatory subunit,
KAPO
P10644  43.0 
Dematin, DEMA Q08495 45.5 
Endoplasmic reticulum resident
protein 44, ERP44
Q9BS26  46.9 
Flotillin-1, FLOT1 O75955 47.4 
Flotillin-2, FLOT2 Q14254 47.1 
Protein disulﬁde-isomerase A1,
PDIA1
P07237  57.1 
Protein disulﬁde-isomerase A6,
PDIA6
Q15084  48.1 
Solute carrier family 2, facilitated
glucose transporter member 1,
GTR1
P11166  54.1 
Thioredoxin domain-containing
protein 5, TXND5
Q8NBS9 47.6 
Tropomodulin-1, TMOD1 P28289 40.6 
55 kDa erythrocyte membrane
protein, EM55
Q00013 52.3 
Annexin A7, ANXA7 P20073 52.7 
26S protease regulatory subunit 8,
PRS8
P62195 45.6 
Ubiquitin-associated
domain-containing protein 1,
UBAC1
Q9BSL1 45.5 
a 13 proteins highlighted in bold were selected for spectral counting.within the normal range. The marginally low platelet count of
140 × 109/l in P2 is likely to be the effect of hydroxycarbamide.
The patients did not have other secondary complications.
Peripheral blood ﬁlm examination did not reveal features
suggestive of myeloﬁbrosis or excess blasts. The reticulocyte
55 kDa which differed between healthy control and PV
ht No. of unique
peptides
Sequence
coverage (%)
Mascot
score
11 26 229
4 12 154
12 29 310
19 49 861
6 13 125
21 51 774
21 43 705
3 9 102
5 14 288
5 11 176
5 12 142
8 28 265
11 23 321
3 5 83
3 5 141
3 6 99
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Fig. 2 – Quantiﬁcation of 40–55 kDa ERMBPs by spectral counting. Basigin (BASI) was used for normalization. PDIA6 and
TXND5 were  up-regulated in 3.2 and 7.9 fold, respectively, in PV patients compared to healthy controls. An asterisk
< 0.0indicates statistical signiﬁcance (Wilcoxon rank sum test, p 
counts performed on the post-refrigerated samples after 3
days revealed a reticulocytopenia.
3.2.  Identiﬁcation  of  human  ERMBPs
ERMBPs were isolated from erythrocytes as previously
described [7], and then separated by SDS-PAGE. To evaluate the
performance of the isolation and identiﬁcation methods, a gel
lane of one of the healthy controls was cut into 14 slices. Pro-
teins were in-gel digested and analyzed by LC–MS/MS. In total
41 proteins were identiﬁed by the Mascot database search with
minimum requirements of two peptides per protein, protein
and peptide conﬁdence of 99% and 95%, respectively. The com-
plied list of all identiﬁed proteins is shown in Supplementary
Table 2. The most abundant erythrocyte associated proteins
Table 3 – Validation of the differentially regulated ERMBPs by X
Protein and entry name Protein abundan
patients/health
XIC data 
Actin, cytoplasmic 1, ACTB 0.94 
Dematin, DEMA 0.57 
Endoplasmic reticulum resident protein
44, ERP44
1.64*  
Solute carrier family 2, facilitated glucose
transporter member 1, GTR1
1.41  
55 kDa erythrocyte membrane protein,
EM55
1.43 
Protein disulﬁde-isomerase A1, PDIA1 1.86* 
Protein disulﬁde-isomerase A6, PDIA6 2.78* 
cAMP-dependent protein kinase type
I-alpha regulatory subunit, KAPO
1.19  
Thioredoxin domain-containing protein
5, TXND5
2.79*  
a An asterisk represents ratios >1.5.
b An asterisk represents p < 0.05.5). Error bars represent SD.
were spectrin alpha chain, spectrin beta chain, ankyrin, band
3 anion transport protein, erythrocyte membrane protein band
4.1 and erythrocyte membrane protein band 4.2. These were
mostly identiﬁed in the vicinity of their known molecular
weight. On the basis of their GO annotation (Scaffold), 30 of
the identiﬁed proteins were membrane located/associated,
i.e. assigned as ERMBPs (Supplementary Figure 1). The iden-
tiﬁcation of extracellular proteins such as serum albumin, Ig
gamma chain or ﬁbrinogen gamma chain is to be expected as
they may have bound to a mature erythrocyte or be present
as contaminants. Even though a mature erythrocyte does
not have a nucleus or other organelles, nuclear and endo-
plasmic reticulum associated proteins were observed in our
data. In this respect many  of the proteins were reported to
IC and SRM methods.
ce ratio (PV
y controls)a
Wilcoxon rank sum test
(p value)b
SRM data XIC data SRM data
1.36 0.406 0.063
0.96 0.031* 0.313
1.57* 0.062 0.031*
0.95 0.906 0.500
1.20 0.781 0.219
3.46* 0.094 0.031*
2.44* 0.031* 0.031*
1.01 0.594 0.500
2.16* 0.031* 0.031*
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Fig. 3 – SRM assay for validating differentially regulated
ERMBPs. (A) Representative data of healthy control (N1) and
PV patient (P1) are shown for a peptide TGEAIVDAALSALR
surrogate of the differentially regulated protein PDIA6. Four
transitions belonging to the precursor ion (m/z 693.8829)
were  compared with a reference spectrum in the library
generated on the Q Exactive instrument. (B) The peak
proﬁles of the peptide were  plotted against the retention
time using Pinpoint software. The area under the curve
was calculated and used for quantiﬁcation. (C) LC retention
time of the targeted peptides was plotted for comparing the
library (Q Exative) and SRM (TSQ Vantage). LC conditions in
both analysis using Q Exactive and TSQ included lineare u  p a o p e n p r o t e o 
e present in multiple subcellular locations such as mem-
rane and nucleus, membrane and endoplasmic reticulum, or
embrane and cytoplasm.
.3.  Quantiﬁcation  of  ERMBPs  by  spectral  counting
n order to detect differentially regulated ERMBPs between PV
atients and healthy controls, proteins from the ﬁve patients
nd controls were separated on gel and compared visually
fter silver staining. Three consecutive gels were prepared. On
ll the replicate gels differences in protein intensity could be
etected between the PV patients and the healthy controls in
he molecular mass area of 40–55 kDa (Fig. 1). Proteins from
his region were cut from each sample lane, in-gel digested
nd analyzed by LC–MS/MS. Altogether 16 proteins were iden-
iﬁed as membrane associated proteins in this mass range
Uniprot) with a minimum of three peptides per protein (see
able 2). Out of these ERMBPs, 13 proteins, identiﬁed in at least
our of the PV patients or four of the healthy controls, were
elected for quantiﬁcation (see Table 2 highlighted proteins).
Peptide-spectrum matches obtained from the Mascot
esults were counted manually for each protein in the healthy
ontrols and PV patients (Supplementary Tables 3 and 4).
ormalization of the spectral counts was ﬁrst tested with a
ouse-keeping protein actin (Supplementary Figure 2). How-
ver, while actin was detected as an ERMBP, it is also well
haracterized as an abundant cytoskeletal protein. For quan-
ifying ERMBPs, normalization with an integral membrane
rotein would be preferable to actin. Two of the quanti-
ed proteins are characterized as transmembrane proteins:
olute carrier family 2, facilitated glucose transporter mem-
er 1 (GTR1) and basigin. GTR1 could not be used for the
ormalization purpose as it was not detected in two of the con-
rol samples, but basigin was observed from all the samples
Supplementary Table 4). Furthermore, when normalized with
ctin, the spectral counts of basigin appeared to be relatively
onstant between the patients and controls (Supplementary
igure 2). Basigin is present in erythrocyte membranes and
 determinant for the Ok blood group system [27]. To our
nowledge expression changes of basigin in the surface of
ature erythrocytes has not been reported, although it has
een shown to be regulated as a receptor for Malaria falciparum
27]. On the basis of our data and the literature, basigin was
hosen as a reference protein for normalizing the quantitative
ata of ERMBPs in this study.
Statistical signiﬁcance of protein abundance changes was
btained by applying Wilcoxon rank sum test for each protein.
his is a non-parametric alternative to the two  sample t-test,
nd is based solely on the order in which the observations
rom the two samples fall [28]. Comparisons of the healthy
ontrols versus the PV patients revealed that protein disulﬁde
somerase A6 (PDIA6) and thioredoxin domain-containing pro-
ein 5 (TXND5) were signiﬁcantly induced in the PV patients
ith ratios 3.2 and 7.9, respectively (Fig. 2). Even though the
p-regulation of these proteins in the PV patient samples
ere detected, their spectral counts, as well as those of basi-
in, were relatively low compared to other common ERMBPs;
ematin (DEMA), ﬂotillin-1 (FLOT1), ﬂotillin-2 (FLOT2), cAMP-
ependent protein kinase type 1-alpha regulatory subunit
KAPO), 55 kDa erythrocyte membrane protein (EM55), actin
ytoplasmic 1 (ACTB), present in Fig. 2. Therefore we chose to
40 min  gradient for peptide separation. The observed linear
correlation between the two LC workﬂows was 0.995.
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Table 4 – Major functions of the ERMBPs up-regulated in PV patients.
Protein Major functionsa Associated
diseases/conditions
References
Protein disulﬁde
isomerase A1
Isomerase activity HIV-1 [37]
Enhance protein folding Acute myeloid leukemia [38]
Electron carrier activity Ovarian cancers [39]
Oxidoreductase activity
Protein disulﬁde
isomerase A6
Isomerase activity Chronic lymphatic
leukemia
[40]
Enhance protein folding Multiple myeloma [41]
Electron carrier activity Glioma [42]
Oxidoreductase activity Hepatocellular carcinoma [43]
Prostate cancer [44]
Cervical cancer [45]
Thioredoxin
domain-containing
protein 5
Isomerase activity Gastric cancer [46]
Enhance protein folding Lung cancer [47]
Electron carrier activity Hepatocellular carcinoma [48]
Oxidoreductase activity Androgen independent
prostate cancer
[49]
Anti apoptotic activity Colorectal adenoma and
cancer
[50]
Cellular membrane organization
Belongs to the pathway of
membrane trafﬁcking
Endoplasmic
reticulum resident
protein 44
Isomerase activity Lipid  homeostasis in
cardiovascular
disease and type 2
diabetes
[29]
Enhance protein folding
Electron carrier activity
Oxidoreductase activity
Participate in the glycoprotein
metabolism
a UniprotKB/Swiss-Prot database (http://www.uniprot.org/uniprot).
verify the quantiﬁcation results using precursor ion intensi-
ties.
3.4.  Quantiﬁcation  of  differentially  regulated  ERMBPs
based  on  precursor  ion  intensities
Based on the spectral counting results we  selected eight pro-
teins, DEMA, EM55, KAPO, GTR1, ERP44, PDIA6, PDIA1 and
TXND5 for further quantiﬁcation. Actin, as well as basigin,
was included as house-keeping proteins. Precursor ion inten-
sities of all the identiﬁed unique peptides were measured on
XICs, which were summed up for each protein and normal-
ized to basigin. The protein abundance changes and statistical
signiﬁcance (Wilcoxon rank sum test) between PV patients
and healthy controls are shown in Table 3. The XIC inten-
sity based quantiﬁcation results were in keeping with the
spectral counting results (refer to Fig. 2). PDIA6 and TXND5
showed signiﬁcantly increased levels (approximately 2.8 fold)
in the PV patients. Even though the changes in PDIA1 and
ERP44 were not statistically signiﬁcant (p > 0.05), increases of
1.9 and 1.6 fold, respectively, were indicated in the patients.
Although DEMA was observed at a signiﬁcantly higher level in
the healthy controls than in the PV patients, it is noted that
it is highly abundant in the erythrocyte cytoskeleton and this
ﬁnding could be compromised.
3.5.  Validation  of  the  differentially  regulated  ERMBPs
using  SRM
To validate the precursor intensity based quantiﬁcation
results, the same erythrocyte membrane samples were
in-solution digested and measured by SRM analysis. Theintensity ratios of all primary and secondary transitions in the
iSRM measurements were compared with the spectral library
to assure that the major fragment ions were matched. Peptides
with Dot Product correlation coefﬁcients (in Pinpoint) above
0.85 were accepted. For quantiﬁcation four transitions per pep-
tide and three unique peptides per protein were monitored
without using the iSRM functionally. Finally 113 transitions
for 36 precursor ions were used in quantiﬁcation (see Sup-
plementary Table 1). The in-solution digests of the PV patient
and healthy control samples were randomized and analyzed
in duplicate. No isotope labeled standard was used, but only
semi-quantitative relative quantitation was performed.
Fig. 3 illustrates data registered in an SRM experiment
with an example peptide “TGEAIVDAALSALR” (m/z 693.8829,
2+), which is a surrogate of the differentially regulated pro-
tein PDIA6. The peptide was eluted from the column at 38.47
and at 38.19 min  in healthy control (N1) and PV patient (P1),
respectively. The relative intensity of the four transitions, m/z
701.43, 816.46, 915.53, and 1028.61, measured for the precur-
sor ion in the healthy control and PV patient samples were
in agreement with a reference spectrum in the library (the
Dot Product correlation coefﬁcient was 0.99) (Fig. 3A). Abso-
lute intensities were compared, all the transitions were higher
in PV patient (P1) than healthy control (N1) (Fig. 3B). The
additional veriﬁcation for the peptides identity was a good
correlation of their retention times with the spectral library
(see Fig. 3C).
The results from the SRM experiment (in-solution digests)
and from the data dependent runs (in-gel digests) are summa-
rized in Table 3. Most of the SRM data (ratio of PV patient to
e u  p a o p e n p r o t e o m i c s 7 ( 2 0 1 5 ) 43–53 51
Fig. 4 – Up-regulation of various PDI family proteins could be involved in the prolonged survival of PV erythrocytes. PDIA1,
PDIA6, ERP 44 and TXND5 reside in ER of immature erythroblasts and reticulocytes, and may be incorporated in mature
erythrocytes. Erythrocytes are exposed to one of the highest levels of oxidative-stress conditions in the body and
thioredoxin domains characteristically tolerate oxidative stress. Since all of those PDI family proteins have 2–3 thioredoxin
domains they can maintain oxidative stress response functions vital for erythrocytes survival. In addition TXND5 has an
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inti-apoptotic function and up-regulation of TXND5 in PV p
ealthy control) correlate with the XIC data. The abundance
f two proteins, PDIA6 and TXND5, increased in the patient
amples in both the experiments. These proteins represented
ore than 2 fold increased values while ERP44 had about
.6 fold increase, which were similar to the XIC data. PDIA1
howed about 3.5 fold increase in the PV patients. Wilcoxon
ank-sum test conﬁrmed all the above results (p < 0.05), i.e. the
ncrease of PDIA6, TXND5, ERP44 and PDIA1 were statistically
igniﬁcant (Table 3). None of other proteins measured showed
igniﬁcant difference.
The four proteins up-regulated in the PV patients belong
o the PDI protein family. The major functions and associ-
ted diseases of the four PDIs are summarized in Table 4. PDIs
sually reside in the endoplasmic reticulum (ER), although
hey can be released to function at the cell surface or extra-
ellular matrix [29]. PDIs function as molecular chaperones
nd as disulphide oxidoreductase/isomerases during protein
olding. The PDI family features two conserved thioredoxin
omains, including an active motif (CGHC) of the disulﬁde
edox response [30,31], and is involved in oxidative stress
esponse [23]. In 2010, Vener et al. found increased oxidative
tress in primary and post PV myeloﬁbrosis [32]. Oxidative
tress is a known up-regulator of thioredoxin expression
31] that provides protection against the stress and has
nti-apoptotic effects [33]. Although non-nucleated mature
rythrocytes were considered to be eliminated by mechanisms
ther than apoptosis, erythrocyte apoptosis has currently
een well acknowledged in the ﬁeld [34–36]. In that context,
ncreased abundance of the 4 PDI proteins having thioredoxints may enhance in the prolonged survival of erythrocytes.
domains may prevent oxidative stress and apoptosis in eryth-
rocytes of PV patients (Fig. 4).
4.  Conclusion
Quantitative proteomics revealed that ERMBPs, PDIA6, TXND5,
ERP44 and PDIA1, were up regulated in the PV patients with
the JAK2 V617F mutation when compared to the healthy con-
trols. Since these four PDI proteins could be considered as an
inhibiting factor of oxidative stress and apoptosis, they may be
associated with the increased red cell mass, which is a cardi-
nal feature in PV (Fig. 4). To our knowledge this is the ﬁrst time
to shed light on the membranes in PV patients. These initial
ﬁndings appear interesting enough to warrant a larger study of
erythrocyte membrane proteins in PV patients. It will be pru-
dent to carry out this work in patients both treated and not
treated with hydroxycarbamide, and/or in vitro experiments
with and without hydroxycarbamide treatment, to negate the
effects of the drug on these ﬁndings. If it is conﬁrmed that the
PDI proteins are in fact differentially regulated in PV patients,
there may be a potential for targeted therapy. On the other
hand, we expect that, as the JAK2 mutation in PV patients acti-
vates the kinase activity, phosphoproteomics approach will
also provide new insights into the mechanism of the disease.Conﬂict  of  interest
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